濮阳东方医院看男科病技术专业(濮阳东方医院收费低不低) (今日更新中)

SAN DIEGO (KGTV) -- The cost of housing in California isn’t just affecting first-time home buyers, it’s also taking a toll on retirees, according to a report from Global Atlantic Financial Group. The research, based on data from more than 4,000 people nationwide, found that retirees in California spend nearly ,575 a month: 30 percent more than the average retiree in the U.S. at ,008.Housing costs that build up during working years also take a toll. Nearly half of California’s non-retired residents ages 40 and up owe an average of 4,876 on their mortgages, compared to the national average of 4,770. Global Atlantic claims that sky-high housing expenses force California residents to make sacrifices during retirement, including cutbacks on restaurants and entertainment, travel and vacations and charitable giving. Almost 40 percent of retirees nationwide are spending more than they expected."Many Americans adjust their lifestyles and cut spending once they see how quickly costs can add up in retirement," says Paula Nelson of Global Atlantic. She says it's an important lesson for those currently in the workforce to understand. "While older retirees are collecting income from employer-sponsored retirement plans, such as pensions, younger and future retirees may not receive the same benefits. Not only have pensions gradually become less common, but the data shows that younger retirees are also less likely to have much saved in other defined contribution plans, like 401(k)s," says Nelson.More than half of retirees wish they'd handled their financial planning differently, according to analysts. The top three regrets include not saving enough, relying too much on Social Security, and not paying down debt before retiring. 1758

SAN DIEGO (KGTV) – The Marine Corps Air Station Miramar said a suspicious letter received by the post office was found not to contain anything harmful Tuesday.MCAS originally sent out a tweet stating that the post office identified a letter around 1:45 that was determined to be suspicious.First responders were called and took “appropriate actions.” Just after 4:30 p.m. MCAS tweeted that the parcel was screened and did not contain anything harmful.MCAS added that the post office is expected to resume normal operations Wednesday.#Update: The parcel was screened and did not contain anything harmful. The @MCASMiramarCA Post Office will resume normal operations tomorrow.— MCAS Miramar (@MCASMiramarCA) March 7, 2018 727

SAN DIEGO (KGTV) — The commissioner of the Pac-12 says 15-minute testing technology from a San Diego company could be the “game-changer” needed to restart competition in the conference before the end of the year.The Pac-12 is considering restarting college football as early as mid- to late-November, according to ESPN, as long as it can secure approvals from state and county lawmakers in California and Oregon.In some conferences, college football is entering its third week, but Pac-12 schools like USC and UCLA are still in workout mode after the conference voted last month to postpone all sports until 2021 at the earliest.League officials are now revisiting that decision and considering an earlier timeline after signing an agreement with San Diego-based Quidel Corporation to provide rapid antigen testing for all athletes, including daily tests for high-contact sports like football.“The access to rapid result testing that we can implement on even a daily basis with some sports with high contact will be a real game changer for us,” Pac-12 commissioner Larry Scott said after touring Quidel’s facility this month.Most nasal swab tests are genetic tests, or PCR tests, which seek out the genetic code buried inside the virus’ protein shell. These tests are considered the industry standard, but they require processing in a lab to convert RNA into enough readable strands of DNA. Results can sometimes take days.Quidel’s nasal swab test is what’s called an antigen test, which looks for parts of the virus’ protein shell. It can be read by machines at each university in about 15 minutes.“No one's going to be spreading the virus because no one will be engaging in practice or competition with the virus,” Scott said.That’s the hope at least, but the partnership with the Pac-12 will be an important test for Quidel’s diagnostic product.Quidel was the first company to get a rapid antigen test on the market, securing an emergency use authorization in May. But there were questions about the accuracy of the test compared to PCR tests in the small sample size provided by the company.In July, Quidel published more data showing its antigen tests matched up with PCR tests 96.7% of the time when a positive was detected. But those results were only among individuals who were actually showing symptoms.“The question that people have is in the asymptomatic population, will the data look similar?” said Quidel CEO Doug Bryant in an interview.Bryant said the company has unpublished data that will be forwarded to the FDA showing “very similar” relative accuracy to PCR tests in asymptomatic individuals, but he said the goal of the partnership with the Pac-12 is to investigate the tests even further.“We want to know that the tests we’re doing are appropriate for use in the asymptomatic population. And we need to demonstrate that, to not only the scientific community but to the public at large,” Bryant said.The testing program with the Pac-12 will essentially be a large clinical trial to find out if rapid testing of athletes can prevent spread, backed by the muscle at some of the premiere research universities.The Pac-12 is hoping the testing program will convince lawmakers to ease restrictions on college athletics, particularly in California.Although the NFL played a game at the new SoFI Stadium in Inglewood last weekend, nearby USC cannot gather in groups of more than 12 players.There are now four antigen tests on the market. Quidel plans to roll out its Sofia 2 testing machines to Pac-12 universities later this month. 3554

SAN DIEGO (KGTV) -- The ACLU is threatening to sue ICE over a policy that forbids detention center volunteers from speaking with the press.Souls Offering Loving and Compassionate Ears, also known as SOLACE, is not allowed to help at the Otay Mesa Detention Center until they sign a form promising not to speak with the media.In August, ICE discovered SOLACE wasn’t in compliance with their protocol before asking the group to resubmit the paperwork for their volunteers.ICE says the code of ethics is in place for the safety of the detainees. “These are often folks who don't have any family or friends in the United States so even if they could write or call they don't have anyone to connect with,” said Angela Fujii, a social justice coordinator with the First Unitarian Universalist.SOLACE volunteers are ready to help, but they want to make sure they can share with others about the place where things are kept pretty tight.SOLACE was also briefly barred from visiting during the Obama Administration but the compromise was met.Other groups are providing detainees with services, but SOLACE was the only one allowed to regularly visit. 1148

SAN DIEGO (KGTV) — The back-to-back announcements of promising clinical trial results from Pfizer and Moderna may usher in a new era for vaccine technology.Both companies have candidates that rely on a new kind of vaccine strategy: RNA. Preliminary data show both candidates are more than 90 percent effective.On the surface, the vaccine candidates look like any other you’ve taken. They work by training your body to build up defensive weapons against a virus, like antibodies and T-cells.But instead of training your body by introducing a killed virus or a fragment of a virus, the vaccines from Moderna and Pfizer introduce a set of instructions called messenger RNA enclosed in a little blob of fat.“The key concept of RNA is that they’re messages, and they’re meant as short-term messages,” said Dr. Shane Crotty of the La Jolla Institute for Immunology.Crotty said there are 5,000 to 10,000 messages within a cell at any given time.Once administered, the mRNA in the vaccine instructs some of your cells to make the coronavirus’ signature spike protein. The spike protein on the surface of the coronavirus allows it to infiltrate and hijack cells.Even though the spike protein is just one of about 25 genes the virus has, preliminary results from the clinical trials suggest it is enough material to train the immune system without making the recipient sick.Crotty likened the process of training the immune system to spotting a sedan. If the coronavirus is a car, the spike protein might be the door.“There's no way that car door could turn into a whole car, but it's enough of a piece of a car for your immune system to recognize that car if it saw it again,” he said.Scientists started by sequencing the virus’ DNA from a sick patient, then encoding that genetic sequence into an mRNA instruction molecule that can be read by the manufacturing part of cells.From there, Dr. Crotty said it’s a bit like the messenger app Snapchat.The mRNA gets injected into the body, sending temporary instructions to your cells that last for a while, then disappear. mRNA does not genetically modify cells, he stressed.“They’re around as messages for some period of time and then they go away, and the cells get back to their normal job of reading their own messages instead of reading the messages you’re injecting in the vaccine,” he said.The concept has been around since the 1990s, but there are currently no RNA vaccines on the market for any pathogen, so Dr. Crotty said it’s hard to estimate how long their protective effects will last.Some vaccines offer a lifetime of protection, like the measles vaccine. Others offer decades of protection. The flu vaccine only lasts about six months.Dr. Crotty said the length of protection depends on how fast the virus mutates and how long the immune cells survive in the body.But even if the COVID-19 vaccine turns out to need an annual update, he’s optimistic. The best feature of RNA vaccines is that they can be quickly reprogrammed.Both Moderna and Pfizer are still in their Phase 3 trials, but they expect to finish them by December. Together, they estimate they’ll have enough doses for about 35 million people by the end of this year, primarily for healthcare workers and high-risk individuals. 3250

来源：资阳报